Celebrating 25 Years of Innovation at MaxCyte
MaxCyte, Inc. (Nasdaq: MXCT; LSE: MXCT) proudly celebrates a milestone this year, marking 25 years of groundbreaking innovation in cell engineering and therapeutic development. Since its inception, MaxCyte has focused on providing the life sciences community with essential technologies and unwavering support for the development of transformative biomedical solutions designed to enhance human health.
Advancing Cell Engineering with Flow Electroporation
At the core of MaxCyte's success is its pioneering Flow Electroporation technology, which was engineered to revolutionize the way cells are handled and modified. Maher Masoud, President and CEO of MaxCyte, emphasizes the commitment to customer needs: "From the beginning, we envisioned commercializing Flow Electroporation, and we have continually expanded our offerings through innovative products crafted within our proprietary ExPERT™ platform. Today, our electroporation solutions are among the best in the industry, ensuring that we support our customers in their scientific endeavors.”
Collaboration with Industry Leaders
One of the notable achievements over the years includes the development of CASGEVY, the first FDA-approved non-viral cell therapy. This groundbreaking development was made possible through strategic collaborations under the Strategic Platform License (SPL) agreements, particularly with Vertex Pharmaceuticals and CRISPR Therapeutics. To date, MaxCyte has established 29 SPL agreements with numerous cell therapy innovators across various therapeutic areas.
New Headquarters to Support Growth
In a strategic move to bolster its capabilities further, MaxCyte relocated to a new, expansive 67,000 square-foot facility in the vibrant I-270 biotech corridor in Maryland. This move not only enhances MaxCyte's manufacturing capacity but also expands its research and development capabilities, enabling the company to keep pace with the rapidly evolving landscape of cell therapy.
Commitment to the Future
Reflecting on these developments, Maher Masoud states, “The progress we’ve made over the last 25 years is significant. As cell engineering continually evolves, we remain dedicated to exploring new methodologies in advanced cell and gene therapy. Our expertise in electroporation technology empowers us to assist customers in pushing the boundaries of biological medicines and improving patient outcomes.”
About MaxCyte
MaxCyte is dedicated to the field of cell engineering, relentlessly working to maximize the potential of cells for the benefit of patients. The company has dedicated over two decades to perfecting its technology and expanding its offerings, including the sophisticated ExPERT™ platform that supports the booming cell therapy market.
Innovative Product Line
The ExPERT family of products includes various instruments such as the ATx™, STx™, GTx™, and VLx™, alongside a comprehensive portfolio of proprietary processing assemblies and supporting software protocols. With robust intellectual property backing its innovations, MaxCyte aims to equip partners with the tools needed for the successful commercialization of next-generation cell-based therapies.
Frequently Asked Questions
What is MaxCyte known for?
MaxCyte is renowned for its innovative Flow Electroporation technology, which supports the development and commercialization of cell-based therapeutics.
How has MaxCyte contributed to cell therapy advancements?
MaxCyte has established numerous strategic partnerships, leading to significant developments, including the first FDA-approved non-viral cell therapy, CASGEVY.
What products does MaxCyte offer?
The company offers the ExPERT™ platform and a range of related instruments and software that facilitate the transfection workflow for cell therapies.
Why is MaxCyte's new headquarters important?
The new headquarters bolster MaxCyte's manufacturing and research capabilities, allowing it to better meet the demands of a growing market in cell therapy.
How does MaxCyte support its partners?
MaxCyte provides scientific, technical, and regulatory support alongside its technology platform to help partners navigate the complexities of bringing cell-based medicines to market.
